within Pharmacolibrary.Drugs.ATC.A;

model A10BK07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.93,
    Cl             = 11.7 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,
    adminCount     = 1,
    Vd             = 0.09209999999999999,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.009333333333333334,
    Tlag           = 24.0
  );

  annotation(Documentation(
    info ="<html><body><p>Luseogliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used primarily for the treatment of type 2 diabetes mellitus. It works by inhibiting glucose reabsorption in the kidney leading to increased urinary glucose excretion. Luseogliflozin is approved for use in Japan and some other countries but is not globally available.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult Japanese volunteers after a single oral dose under fasting conditions.</p><h4>References</h4><ol><li><p>Seino, Y (2014). Luseogliflozin for the treatment of type 2 diabetes. <i>Expert opinion on pharmacotherapy</i> 15(18) 2741–2749. DOI:<a href=&quot;https://doi.org/10.1517/14656566.2014.978290&quot;>10.1517/14656566.2014.978290</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25359155/&quot;>https://pubmed.ncbi.nlm.nih.gov/25359155</a></p></li><li><p>Sasaki, T, et al., &amp; Samukawa, Y (2014). Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial. <i>Advances in therapy</i> 31(3) 345–361. DOI:<a href=&quot;https://doi.org/10.1007/s12325-014-0102-3&quot;>10.1007/s12325-014-0102-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24535625/&quot;>https://pubmed.ncbi.nlm.nih.gov/24535625</a></p></li><li><p>Sasaki, T, et al., &amp; Samukawa, Y (2015). Absence of Drug-Drug Interactions Between Luseogliflozin, a Sodium-Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males. <i>Advances in therapy</i> 32(5) 404–417. DOI:<a href=&quot;https://doi.org/10.1007/s12325-015-0209-1&quot;>10.1007/s12325-015-0209-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25975816/&quot;>https://pubmed.ncbi.nlm.nih.gov/25975816</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A10BK07;
